Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Colorcon
Baxter
Boehringer Ingelheim

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

TRIENTINE HYDROCHLORIDE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Trientine Hydrochloride patents expire, and when can generic versions of Trientine Hydrochloride launch?

Trientine Hydrochloride is a drug marketed by Amneal Pharms Llc, Dr Reddys Labs Ltd, Kadmon Pharms Llc, Msn Labs Pvt Ltd, Navinta Llc, Par Pharm Inc, Watson Labs Teva, and Zydus Pharms. and is included in eight NDAs.

The generic ingredient in TRIENTINE HYDROCHLORIDE is trientine hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the trientine hydrochloride profile page.

Drug patent expirations by year for TRIENTINE HYDROCHLORIDE
Recent Clinical Trials for TRIENTINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GMP-Orphan SASPhase 3
University of British ColumbiaPhase 2
Univar BVPhase 4

See all TRIENTINE HYDROCHLORIDE clinical trials

Pharmacology for TRIENTINE HYDROCHLORIDE
Drug ClassMetal Chelator
Mechanism of ActionMetal Chelating Activity
Medical Subject Heading (MeSH) Categories for TRIENTINE HYDROCHLORIDE
Synonyms for TRIENTINE HYDROCHLORIDE
1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, dihydrochloride
1,2-Ethanediamine,N1,N2-bis(2-aminoethyl)-, hydrochloride (1:2)
2,2'-Ethylenediiminobis(ethylamine) dihydrochloride
260T014
38260-01-4
AC1L2G5T
AC1Q3AVT
ACMC-1AD6N
AKOS028109579
API0004500
C-49679
C6H20Cl2N4
CCG-213505
CHEBI:9706
CHEMBL3989777
CTK8C5369
Cuprid
D00736
DB-049259
DTXSID2057863
EINECS 253-854-3
FT-0639448
HC3NX54582
Laszarin
LS-65337
Metalite
MK 0681
MK-0681
MK-681
N,N'-Bis(2-aminoethyl)-1,2-ethanediamine dihydrochloride
n,n'-bis(2-aminoethyl)ethan-1,2-diamindihydrochlorid
N,N'-bis(2-aminoethyl)ethane-1,2-diamine dihydrochloride
N,N'-Bis(2-aminoethyl)ethylenediamine dihydrochloride
N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine dihydrochloride
N\'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine,dihydrochloride
N1,N1'-(ethane-1,2-diyl)diethane-1,2-diamine dihydrochloride
PubChem21105
SCHEMBL506189
Syprine
Syprine (TN)
TC-164812
TJA-250
Trien dihydrochloride
Trientine Dihydrochloride
Trientine HCl
Trientine hydrochloride (JP17/USP)
Trientine hydrochloride [USAN:USP]
Trientine hydrochloride [USAN]
Trientine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Trientine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Triethylene tetramine dihydrochloride
Triethylenetetramine dihydrochloride
Triethylenetetramine Dihydrochloride (Trientine Hydrochloride )
Triethylenetetramine dihydrochloride, puriss., 2xcryst., >=99.0% (AT)
UNII-HC3NX54582
WYHIICXRPHEJKI-UHFFFAOYSA-N

US Patents and Regulatory Information for TRIENTINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms Llc TRIENTINE HYDROCHLORIDE trientine hydrochloride CAPSULE;ORAL 210619-001 Feb 8, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva TRIENTINE HYDROCHLORIDE trientine hydrochloride CAPSULE;ORAL 207567-001 Feb 7, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Msn Labs Pvt Ltd TRIENTINE HYDROCHLORIDE trientine hydrochloride CAPSULE;ORAL 211134-001 May 22, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Zydus Pharms TRIENTINE HYDROCHLORIDE trientine hydrochloride CAPSULE;ORAL 211554-001 Apr 26, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
McKesson
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.